John Tan MBA, M.Eng, CLSSBB, CSM, SA

Experience

• 

  Ministry of Defence of Singapore

  Jan 2001 - Jan 2004

  Policy Manager

  • Analyzed developments in US defense sector and formulated strategies and policies to manage technology relations with the US and provided timely reports to senior management • Led strategic policy planning and coordination with partners in the defense technology ecosystem

• 

  Ministry of Foreign Affairs Singapore

  Jan 2004 - Jan 2008

  Diplomat in Washington DC

  • Identified and evaluated business opportunities between Singapore and US governments and companies to collaborate in technology areas of mutual interest.• Established 13 information agreements, 19 project agreements (est. value US$23mil) and 4 scientist and engineering exchanges with US Department of Defense (DoD)

• 

  DSTA

  Jan 2009 - Jan 2010

  Project Manager

  • Led a team of engineers in the procurement of aircraft and flight-training device (est. at S$8mil) in a highly accelerated timeframe.• Implemented a performance-based logistics package (est. S$18mil) as part of aircraft acquisition.• Created a cost-benefit analysis model for evaluation using the Analytical Hierarchy Process.

• 

  EDBI Pte Ltd

  Jan 2010 - Jan 2012

  Investment Manager (Medtech)

  EDBI - Bio*One Capital manages a S$1.2billion growth fund that invests in global biotechnology, pharmaceuticals and medical technology companies.• Executed investment opportunities in medical devices and healthcare industries with focus on cardiovascular, diagnostics, ophthalmology, metabolic diseases and healthcare information technology.• Performed financial modelling, valuation, business due diligence, term sheet negotiations and financial transaction documents with potential investee companies.• Managed an investment portfolio of companies and worked closely with management team and Board of Directors on business performance, operational issues and capitalization, including a NASDAQ listing.• Board of Directors Dx Assays (JV with Qiagen) and Innoheart Show less

• 

  YAMADA Consulting & Spire

  Jan 2012 - Jan 2015

  Country Director, Greater China (China, Hong Kong and Taiwan)

  Spire Research and Consulting is a regional marketing research and consulting firm with offices in 9 countries.• Directed Greater China operations covering China, Hong Kong and Taiwan and acquired new client base in Shanghai and Singapore ($2M P&L)• Managed local team of consultants in Shanghai and Singapore to deliver market insights and market growth strategy consultancy services to Fortune 1000 companies with deep focus in Healthcare, Industrial and Consumer Products.• Advised MNC Clients on competitive and merger & acquisition (M&A) strategy in China and around Asia Pacific region. Show less

• 

  Ministry of Health (Singapore)

  Jan 2015 - Jan 2018

  Deputy Director

  • Successfully expanded national aged care strategy by delivering ~4,000 new beds (36% increase in capacity) across 13 new government-built nursing homes from 2015 to 2017. • Drove market development and growth strategy and analysed aged care industry supply and demand and provided recommendations to long-term 2030 strategic planning.• Led portfolio mapping and gap analysis to identify current gaps as well as new business opportunities up to 2020. Developed market and operational strategies for Vanguard Healthcare Pte Ltd, a private company owned by Government.• Implemented Singapore Government’s “Build-Own-Lease” Nursing Home Program (Public-Private Partnership) est. at S$1b. • Developed “Go-to-Market” strategy and supporting healthcare financing for new aged care products services, including pricing and bidding strategies to achieve desired strategic market outcomes, incubating and piloting new aged care service models such as the “Short-Stay Unit”. Show less

• 

  Envista Holdings Corporation

  Jan 2018 - Jan 2022

  APAC Director of Marketing & Strategy, Envista Business Systems Leader

  Envista Co (NYSE: NVST) is one of the largest global dental product companies with product portfolio of more than 30 brands spanning KAVO, Dexis, KERR, ORMCO, and Nobel BioCare.• Successfully turned around business to positive core growth from -4% (2017) to +8% (2019). Post COVID recovery with DD (+15%) growth end 2021. • Member of APAC senior management overseeing 5 regional clinical marketing professionals. Responsible for ~500 associates, $250m annual revenue.• Set up APAC regional marketing structure and policies across JPN, ANZ, IND, SEA, KOR, TW and HK.• Directed regional and local GTM and marketing strategies in local countries based on Voice-of-customers and regional commercial strategy.• Drove revenue growth and direct margins expansion by developing new business opportunities, KOL development & engagement, Transformative Marketing framework.• Formulated and executed regional marketing plans, go-to-market business transformations incl. multi-channel expansion and hybrid strategies, pricing strategies and new product launches to gain market shares• Partnered with country leaders to improve forecast predictability and funnel visibility (MQL & SQL tracking), resolve backorders and align sales/channel partners incentive plans. Implemented price increase (average +3% p.a) to drive profitability.• Pioneered T&E strategies and KOL engagement plan as part of APAC level professional clinical marketing. Expanded local and regional KOLs from 20 to 80 in 2 years.• Generated competitive and market trends analysis for actionable insights, strategy hypothesis for investment plans in growth segments. APAC M&A project management lead for Carestream Intra-oral Scanner acquisition and Medit partnership.• Led Kaizen initiatives and problem solving teams on salesforce effectiveness, sales & commercial excellence, forecast predictability. Implemented visual and daily management tool for marketing dashboard reporting. Show less

• 

  Danaher Corporation

  May 2018 - Apr 2022

  Asia Pacific Director Strategy & Marketing and DBSL, Dental Platform

  • Successfully turned around business to positive core growth from -4% (2017) to +8% (2019). Post COVID recovery with DD (+15%) growth end 2021. • Member of APAC senior management overseeing 5 regional clinical marketing professionals. Responsible for ~500 associates, $250m annual revenue.• Set up APAC regional marketing structure and policies across JPN, ANZ, IND, SEA, KOR, TW and HK.• Directed regional and local GTM and marketing strategies in local countries based on Voice-of-customers and regional commercial strategy.• Drove revenue growth and direct margins expansion by developing new business opportunities, KOL development & engagement, Transformative Marketing framework.• Formulated and executed regional marketing plans, go-to-market business transformations incl. multi-channel expansion and hybrid strategies, pricing strategies and new product launches to gain market shares• Partnered with country leaders to improve forecast predictability and funnel visibility (MQL & SQL tracking), resolve backorders and align sales/channel partners incentive plans. Implemented price increase (average +3% p.a) to drive profitability.• Pioneered T&E strategies and KOL engagement plan as part of APAC level professional clinical marketing. Expanded local and regional KOLs from 20 to 80 in 2 years.• Generated competitive and market trends analysis for actionable insights, strategy hypothesis for investment plans in growth segments. APAC M&A project management lead for Carestream Intra-oral Scanner acquisition and Medit partnership.• Led Kaizen initiatives and problem solving teams on salesforce effectiveness, sales & commercial excellence, forecast predictability. Implemented visual and daily management tool for marketing dashboard reporting. Show less

• 

  Danaher Corporation

  Oct 2022 - now

  Japan APAC Commerical Growth DBS Director - Leica Microsystems

  • Led Global Policy Deployment Kaizen on Channel Partner Excellence Program. Implemented regional assessment scorecard and incentives program for APJ countries with top Channel Partners signup responsible for more than $20m of annual revenue contributions.• Rolled out Funnel Management Situational Leadership 2.0 program. Coached sales team on improving funnel creation and conversion. Improved visits per week, % opportunities with follow up actions, funnel conversion and funnel creation by >50% in Q1 2024 leveraging SFDC.• Improved market visibility by +11% vs 2022 by working with marketing teams on transformational marketing initiatives.• Expanded Channel Partner business contribution by +7% vs 2022 by rolling out CP Building Standard Work across India, Japan, Australia and Thailand.• Implemented Key Accounts Management Strategy in High Density Geography starting in Australia (Sydney and Melbourne). Identified $14m incremental opportunities from 2024-2026. • Strengthened commercial execution with standardized funnel review meetings across APJ. Sustained overall win-rate at >50%.• Improved India working capital turn from 4 to 4.8 with Quote-to-Cash kaizen. Reduced $1.1m excess inventory.• Worked with Australia to improve Demo inventory utilization rate from 30% to 70%.• Coached and motivated teams in the proliferation of continuous improvement culture. Developed 5 new certified practitioners and trained more than 154 associates in DBS Show less